Context: Treatment-related toxicities in DLBCL (diffuse large B cell lymphoma) patients are higher in the initial phase of treatment (first cycle effect). Implementation of pre-phase treatment before definitive chemotherapy had been shown to alleviate some of these side-effects in a non-randomized study conducted earlier in our institute (Lakshmaiah et. al., Eur J Haematol 100:644-8, 2018).
Aims: This study was aimed at validating the role of pre-phase treatment in newly diagnosed DLBCL patients.
Settings And Design: All newly diagnosed patients with DLBCL above the age of 18 years were evaluated for eligibility and prospectively enrolled. A single-arm prospective study was conducted at the Department of Medical Oncology, in our institute from July 2015 to December 2019.
Methods And Material: Patients received vincristine and prednisolone as pre-phase treatment for 7 days after which definitive chemotherapy was instituted on day 1. They were followed up for 30 days post-first cycle chemotherapy.
Statistical Analysis Used: Paired Student's t tests and Wilcoxon signed-ranks test were used for comparison of various clinical variables as appropriate. P value of less than 0.05 was considered significant.
Results: Among the 180 patients who were included in study, performance status improvement was noted in significant number of patients (p < 0.001). 38.4% achieved an ECOG (Eastern Cooperative Oncology Group) performance status of 0 post-pre-phase therapy. Febrile neutropenia was observed in 12.8% in the present cohort as compared to the historical non-pre-phase cohort (34%).
Conclusions: Pre-phase therapy significantly improves the performance status and diminishes neutropenia rates in DLBCL patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s43046-022-00116-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extreme hyperleukocytosis (Leukocyte count >200 × 10/L) in an adolescent young adult (AYA) patient with B-ALL could result in mild symptoms of leukostasis. Hyperleukocytosis requires prompt initiation of therapy with adequate hydration, cytoreduction and prevention of tumor lysis. Ph + B-ALL may present with extreme hyperleukocytosis and may be resistant to initial pre-phase therapy.
View Article and Find Full Text PDFEffectiveness of Paliperidone Palmitate on Treatment Adherence and Relapse in the Adult Schizophrenia Population: A One-Year Mirror-Image Study in a Colombian Mental Health Care Facility.
Rev Colomb Psiquiatr (Engl Ed)
December 2024
YolaRX Consultants, Montreal, Quebec, Canada; Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States of America. Electronic address:
Introduction: The benefits of long-acting injectable antipsychotics have been documented in several observational studies, but data remain scarce in Latin America. This study aimed at evaluating the effectiveness of paliperidone palmitate once monthly (PP1M) on treatment adherence and relapse in the schizophrenia population followed in a government-funded mental health care facility in Colombia.
Methods: A mirror-image study was conducted.
Primary Oesophageal Lymphoma: A Diagnostic Dilemma.
Cureus
November 2024
Gastroenterology, Wythenshawe Hospital, Manchester, GBR.
Article Synopsis
- * A 78-year-old male with dysphagia underwent several diagnostic procedures, ultimately confirming a diagnosis of diffuse large B-cell lymphoma (DLBCL) after various initial findings were misattributed to less severe conditions.
- * The rapid progression of the disease in this patient underscored the need for prompt recognition of primary oesophageal lymphoma, especially in older individuals, and ultimately shifted the focus to palliative care due to the aggressive nature of the illness.
Role of Clinical Pharmacy anticoagulation service on Apixaban prescribing appropriateness in atrial fibrillation in Saudi Arabia.
Curr Probl Cardiol
June 2024
Cardiology Center, King Abdullah Medical City, Makkah, KSA, Saudi Arabia; Cardiology Department, Faculty of Medicine, Zagazig University, Egypt.
Background: Inappropriate DAOC dosing is precuarious and frequently encountered. Apixaban is the most reported DOAC to be inappropriately dosed. We examined the effect of adding a Clinical Pharmacist to the cardiology team rounds to the standard practice in Apixaban prescription patterns in a tertiary center in KSA.
View Article and Find Full Text PDFFirst-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study.
Infect Dis Ther
February 2024
Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Article Synopsis
- * The study, conducted from July 2014 to May 2015, involved 52 participants and found that 30% of those receiving KB experienced adverse events, the most common being headaches and influenza, while fewer adverse events occurred in the placebo group.
- * Results revealed that KB has a non-linear pharmacokinetic profile, with a plasma elimination half-life of 1.61-4.24 hours, and it showed favorable safety and tolerability across the tested dosage
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!